EyePoint Pharmaceuticals

92 articles with EyePoint Pharmaceuticals

• EyePoint Pharmaceuticals to Present at the H.C Wainwright Global Healthcare Investment Conference

  5/17/2022

  EyePoint Pharmaceuticals, Inc. announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will present at the H.C Wainwright Global Healthcare Investment Conference.

• EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - May 16, 2022

  5/16/2022

  EyePoint Pharmaceuticals, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635.

• EyePoint Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Developments

  5/4/2022

  EyePoint Pharmaceuticals, Inc. today announced financial results for the first quarter ended March 31, 2022 and highlighted recent corporate developments.

• EyePoint Pharmaceuticals Announces Expanded License Agreement with Betta Pharmaceuticals for EYP-1901 in China, Hong Kong, Macau and Taiwan

  5/4/2022

  EyePoint Pharmaceuticals, Inc. today announced the execution of a license agreement with Betta Pharmaceuticals Co. Ltd. (SHE: 300558) to develop and commercialize EYP-1901 in Mainland China, Hong Kong, Macau and Taiwan.

• EyePoint Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022

  4/27/2022

  WATERTOWN, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 4, 2022 to report its first quarter 2022 financial results and highlight recent corporate developments.

• EyePoint Pharmaceuticals to Participate in Fireside Chat at the B. Riley 2022 Virtual Neuro & Ophthalmology Conference

  4/21/2022

  EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will participate in a fireside chat at the B. Riley 2022 Virtual Neuro & Ophthalmology Conference.

• EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Apr 18, 2022

  4/18/2022

  EyePoint Pharmaceuticals, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635.

• EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Mar 16, 2022

  3/16/2022

  EyePoint Pharmaceuticals, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635.

• EyePoint Pharmaceuticals Announces Debt Refinancing with $45M Credit Facilities from Silicon Valley Bank

  3/9/2022

  EyePoint Pharmaceuticals, Inc. today announced that it has entered into a loan agreement providing for senior secured credit facilities in the aggregate amount of $45 million with Silicon Valley Bank to replace its existing credit facility with CRG Servicing LLC (CRG).

• EyePoint Pharmaceuticals Appoints Isabelle Lefebvre as Chief Regulatory Officer

  3/7/2022

  EyePoint Pharmaceuticals, Inc. today announced the appointment of Isabelle Lefebvre as Chief Regulatory Officer.

• EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Developments

  3/3/2022

  EyePoint Pharmaceuticals, Inc. today announced financial results for the fourth quarter and year ended December 31, 2021 and highlighted recent corporate developments.

• EyePoint Pharmaceuticals to Participate in Fireside Chat at the Cowen 42nd Annual Health Care Conference

  3/1/2022

  EyePoint Pharmaceuticals, Inc. announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 10:30 a.m. ET.

• EyePoint Pharmaceuticals Announces Updated Positive Interim Safety and Efficacy Data from Ongoing Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD

  2/12/2022

  EyePoint Pharmaceuticals, Inc. announced updated interim data from the "Durasert® and Vorolanib in Ophthalmology" Phase 1 clinical trial of EYP-1901, a bioerodible sustained delivery intravitreal anti-vascular endothelial growth factor treatment targeting wet age-related macular degeneration.

• 

  BioSpace Movers & Shakers, Jan. 14

  1/14/2022

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• EyePoint Pharmaceuticals Appoints Michael C. Pine as Chief Corporate Development and Strategy Officer

  1/10/2022

  EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced the appointment of Michael C. Pine as Chief Corporate Development and Strategy Officer.

• EyePoint Pharmaceuticals Announces 2022 Clinical Plans and Highlights Recent Corporate and Clinical Achievements

  1/10/2022

  EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), today announced its 2022 clinical pipeline plans and highlighted recent corporate achievements driven by its lead pipeline candidate, EYP-1901, a potential six-month intravitreal treatment targeting wet age-related macular degeneration (wet AMD).

• EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce Expanded U.S. Commercial Alliance for DEXYCU®

  12/7/2021

  EyePoint Pharmaceuticals, Inc. and ImprimisRx jointly announced the expansion of their commercial alliance in which ImprimisRx will assume responsibility for U.S. sales and marketing activities for DEXYCU® 9% for the treatment of post-operative inflammation following ocular surgery in the U.S.

• EyePoint Pharmaceuticals Announces Closing of $115.4 Million Public Offering

  11/19/2021

  EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), today announced the closing of the previously announced underwritten public offering of 5,122,273 shares of its common stock.

• EyePoint Pharmaceuticals Announces Pricing of Public Offering - Nov 17, 2021

  11/17/2021

  EyePoint Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 4,027,273 shares of its common stock at a public offering price of $13.75 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 3,272,727 shares of its common stock at a price to the public of $13.74 per each pre-funded warrant.

• EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock - Nov 16, 2021

  11/16/2021

  EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock.